GMAB News and Press, Genmab A/S From 07/27/23

Company Announcement COPENHAGEN , Denmark; July 2 8 , 20 2 3 – Genmab A/S ( Nasdaq: GMAB ) announced today its preliminary first half 2023 financial results and its updated 2023 financial guidance. ...

Company Announcement The positive CHMP opinion is supported by results from the EPCORE™ NHL-1 phase 1/2 trial evaluating the preliminary efficacy and safety of epcoritamab in patients with non-Hodgkin’s lymphoma (NHL), including diffuse large B-cell lymphoma (DLBCL) ...

2023-07-20 07:37:43 ET Genmab ( GMAB ) said that worldwide net trade sales of DARZALEX (daratumumab), including sales of the subcutaneous product as reported by Johnson & Johnson were $2,431M in Q2 2023. Net trade sales were $1,322M in the U.S. and $1,1...

2023-07-20 07:07:34 ET Johnson & Johnson ( NYSE: JNJ ) added ~2% in the pre-market Thursday after the pharma giant exceeded Wall Street forecasts with its Q2 2023 results, thanks mainly to better-than-expected results from its Pharmaceutical and MedTech segments. The New...

Company Announcement Net sales of DARZALEX ® in the second quarter of 202 3 totaled USD 2,431 million Genmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen) COPENHAGEN, Denmark; July 20...

2023-07-16 20:14:12 ET UK-based HSBC initiated coverage of 19 major biopharma stocks this past week, labeling Roche ( OTCQX:RHHBY ) ( OTCQX:RHHBF ), Merck KGaA ( OTCPK:MKGAF ) ( OTCPK:MKKGY ) and Lonza ( OTCPK:LZAGY ) ( OTCPK:LZAGF ) as potential comeback stories, wh...

2023-07-12 07:51:55 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Artificial intelligence ( AI ) has become an invaluable tool for investors seeking opportunities in the stock market. Its ability to analyze large amounts of data and recognize patterns m...

2023-07-02 09:30:00 ET Epcoritamab, a cancer drug co-developed by AbbVie (NYSE: ABBV) and Genmab (NASDAQ: GMAB) , was recently given the green light by the Food and Drug Administration to be used as a treatment for adults with relapsed or refractory (R/R) diffuse large B-cel...

2023-06-29 10:05:50 ET Summary Genmab's stock has seen negative price action despite the FDA approval of its drug, Epcoritamab, for relapsed/refractory diffuse large B-cell lymphoma (DLBCL). The market has already priced in the approval, and the drug faces a competitive landscape ...

Company Announcement Based on the topline results from the EPCORE™ NHL-1 clinical trial, Genmab and AbbVie will engage with global regulatory authorities to discuss next steps Data from the clinical trial will be presented at a future medical meeting Follicular Ly...